NewAmsterdam Pharma Company NV announced the enrollment of the first patients in the RUBENS Phase 3 clinical trial, evaluating obicetrapib and the obicetrapib/ezetimibe fixed dose combination in patients with metabolic syndrome. Topline results from the RUBENS trial are expected by the end of 2026. Additionally, in June and July 2025, NewAmsterdam presented positive data from a prespecified Alzheimer's disease biomarker analysis from the BROADWAY clinical trial at the 2025 Alzheimer's Association International Conference. The analysis showed statistically significant reductions in plasma p-tau217 levels, a key biomarker of Alzheimer's disease pathology, in both the full analysis set and among ApoE4 carriers. The company also anticipates an EMA approval decision for obicetrapib and the fixed dose combination in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622745) on January 09, 2026, and is solely responsible for the information contained therein.